Do proton pump inhibitors modulate the efficacy of anti-PD-1/PD-L1 therapy? A retrospective study

被引：28
|
作者：
Mukherjee, Sarbajit [1 ]
Ibrahimi, Sami [1 ]
Khalid, Bilal [1 ]
Roman, Darwin [2 ]
Zhao, Daniel [3 ]
Aljumaily, Raid [1 ]
机构：
[1] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Div Hematol Oncol, Oklahoma City, OK USA
[2] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK USA
[3] Univ Oklahoma, Hlth Sci Ctr, Dept Biostat & Epidemiol, Oklahoma City, OK USA
来源：
JOURNAL OF ONCOLOGY PHARMACY PRACTICE | 2019年 / 25卷 / 03期
关键词：
D O I：
10.1177/1078155218771152
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：762 / 764
页数：3
相关论文
共 50 条
  • [21] Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future
    Chen, Lieping
    Han, Xue
    JOURNAL OF CLINICAL INVESTIGATION, 2015, 125 (09): : 3384 - 3391
  • [22] Parameters of Tumor Microenvironment Determine Effectiveness of Anti-PD-1/PD-L1 Therapy
    Tashireva, Liubov A.
    Muravyova, Dariya T.
    Popova, Natalya O.
    Goldberg, Victor E.
    Vtorushin, Sergey V.
    Perelmuter, Vladimir M.
    BIOCHEMISTRY-MOSCOW, 2021, 86 (11) : 1461 - 1468
  • [23] Parameters of Tumor Microenvironment Determine Effectiveness of Anti-PD-1/PD-L1 Therapy
    Liubov A. Tashireva
    Dariya T. Muravyova
    Natalya O. Popova
    Victor E. Goldberg
    Sergey V. Vtorushin
    Vladimir M. Perelmuter
    Biochemistry (Moscow), 2021, 86 : 1461 - 1468
  • [24] TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy
    Yi, Ming
    Li, Tianye
    Niu, Mengke
    Wu, Yuze
    Zhao, Zhenyu
    Wu, Kongming
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [25] Outcomes of anti-PD-1 therapy in mesothelioma and correlation with PD-L1 expression.
    Rivalland, Gareth
    Kao, Steven Chuan-Hao
    Pavlakis, Nick
    Hughes, Brett Gordon Maxwell
    Thapa, Bibhusal
    Pal, Abhijit
    Walkiewicz, Marzena
    Zimet, Allan Solomon
    White, Shane
    O'Byrne, Ken
    Mitchell, Paul
    John, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [26] Impact of Renin-angiotensin System Inhibitors on the Efficacy of Anti-PD-1/PD-L1 Antibodies in NSCLC Patients
    Tozuka, Takehiro
    Yanagitani, Noriko
    Yoshida, Hiroshi
    Manabe, Ryo
    Ogusu, Shinsuke
    Tsugitomi, Ryosuke
    Sakamoto, Hiroaki
    Amino, Yoshiaki
    Ariyasu, Ryo
    Uchibori, Ken
    Kitazono, Satoru
    Seike, Masahiro
    Gemma, Akihiko
    Nishio, Makoto
    ANTICANCER RESEARCH, 2021, 41 (04) : 2093 - 2100
  • [27] HMGB1 assists the predictive value of tumor PD-L1 expression for the efficacy of anti-PD-1/PD-L1 antibody in NSCLC
    Funaishi, Kunihiko
    Yamaguchi, Kakuhiro
    Tanahashi, Hiroki
    Kurose, Koji
    Sakamoto, Shinjiro
    Horimasu, Yasushi
    Masuda, Takeshi
    Nakashima, Taku
    Iwamoto, Hiroshi
    Hamada, Hironobu
    Oga, Toru
    Oka, Mikio
    Hattori, Noboru
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2025, 95 (01)
  • [28] Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy
    Lee, Heng-Huan
    Wang, Ying-Nai
    Xia, Weiya
    Chen, Chia-Hung
    Rau, Kun-Ming
    Ye, Leiguang
    Wei, Yongkun
    Chou, Chao-Kai
    Wang, Shao-Chun
    Yan, Meisi
    Tu, Chih-Yen
    Hsia, Te-Chun
    Chiang, Shu-Fen
    Chao, K. S. Clifford
    Wistuba, Ignacio I.
    Hsu, Jennifer L.
    Hortobagyi, Gabriel N.
    Hung, Mien-Chie
    CANCER CELL, 2019, 36 (02) : 168 - +
  • [29] Efficacy of anti-PD-1 antibodies in NSCLC patients with anEGFRmutation and high PD-L1 expression
    Masuda, Ken
    Horinouchi, Hidehito
    Tanaka, Midori
    Higashiyama, Ryoko
    Shinno, Yuki
    Sato, Jun
    Matsumoto, Yuji
    Okuma, Yusuke
    Yoshida, Tatsuya
    Goto, Yasushi
    Yamamoto, Noboru
    Ohe, Yuichiro
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2021, 147 (01) : 245 - 251
  • [30] PRIMING OF ANTI-PD-1/ PD-L1 THERAPY BY ANTI-METABOLITE CHEMOTHERAPEUTIC AGENTS IN NSCLC
    Lin, Chingwen
    Lin, Peiying
    Yang, Panchyr
    RESPIROLOGY, 2018, 23 : 290 - 290
12345